Molnupiravir Active Metabolite–N4 hydroxycytidine causes Cytotoxicity to Mammalian Cells In Vitro

Pakotiprapha et al., ASPET 2024 Annual Meeting Abstract - Toxicology, doi:10.1124/jpet.212.937140

May 2024

Source PDF All Studies Meta AnalysisMeta

In Vitro study showing cytotoxicity of N4-hydroxycytidine (NHC), the active metabolite of molnupiravir, at concentrations relevant to therapeutic doses of molnupiravir in COR-L23 and HepG2 cancer cell lines, and compared with cytotoxicity in normal HaCaT cells. NHC showed cytotoxicity in all three lines, with HaCaT cells showing lower IC₅₀ values compared to both cancer cell lines at 3 and 5 days of treatment. The therapeutic dose of molnupiravir results in serum NHC concentrations close to the IC₅₀ values obtained in this study.

Potential risks of molnupiravir include the creation of dangerous variants, and mutagenicity, carcinogenicity, teratogenicity, and embryotoxicity1-10. Multiple analyses have identified variants potentially created by molnupiravir11-15.

Important missing comments or errors? Let us know.

1. Swanstrom et al., Lethal mutagenesis as an antiviral strategy, Science, doi:10.1126/science.abn0048.science.org, doi.org.

2. Hadj Hassine et al., Lethal Mutagenesis of RNA Viruses and Approved Drugs with Antiviral Mutagenic Activity, Viruses, doi:10.3390/v14040841.mdpi.com, doi.org.

3. Waters et al., Human genetic risk of treatment with antiviral nucleoside analog drugs that induce lethal mutagenesis: the special case of molnupiravir, Environmental and Molecular Mutagenesis, doi:10.1002/em.22471.wiley.com, doi.org.

4. Huntsman, M., An assessment of the reproductive toxicity of the anti-COVID-19 drug molnupiravir using stem cell-based embryo models, Master's Thesis, scholarspace.manoa.hawaii.edu/items/cd11342c-b4dc-44c0-8b44-ce6e3369c40b.hawaii.edu.

5. Zibat et al., N4-hydroxycytidine, the active compound of Molnupiravir, promotes SARS-CoV-2 mutagenesis and escape from a neutralizing nanobody, iScience, doi:10.1016/j.isci.2023.107786.sciencedirect.com, doi.org.

6. Shiraki et al., Convenient screening of the reproductive toxicity of favipiravir and antiviral drugs in Caenorhabditis elegans, Heliyon, doi:10.1016/j.heliyon.2024.e35331.sciencedirect.com, doi.org.

7. Gruber et al., Molnupiravir increases SARS‐CoV‐2 genome diversity and complexity: A case‐control cohort study, Journal of Medical Virology, doi:10.1002/jmv.29642.wiley.com, doi.org.

8. Marikawa et al., An active metabolite of the anti-COVID-19 drug molnupiravir impairs mouse preimplantation embryos at clinically relevant concentrations, Reproductive Toxicology, doi:10.1016/j.reprotox.2023.108475.sciencedirect.com, doi.org.

9. Zhou et al., β-D-N4-hydroxycytidine Inhibits SARS-CoV-2 Through Lethal Mutagenesis But Is Also Mutagenic To Mammalian Cells, The Journal of Infectious Diseases, doi:10.1093/infdis/jiab247.oup.com, doi.org.

10. Chamod et al., Molnupiravir Metabolite--N4-hydroxycytidine Causes Cytotoxicity and DNA Damage in Mammalian Cells in vitro: N4-hydroxycytidine Induced Cytotoxicity DNA Damage, Asian Medical Journal and Alternative Medicine, 23:3, asianmedjam.com/index.php/amjam/article/view/1448.asianmedjam.com.

11. Focosi et al., The fitness of molnupiravir-signed SARS-CoV-2 variants: imputation analysis based on prescription counts and GISAID analyses by country, Intervirology, doi:10.1159/000540282.karger.com, doi.org.

12. Sanderson et al., A molnupiravir-associated mutational signature in global SARS-CoV-2 genomes, Nature, doi:10.1038/s41586-023-06649-6.nature.com, doi.org.

13. Fountain-Jones et al., Effect of molnupiravir on SARS-CoV-2 evolution in immunocompromised patients: a retrospective observational study, The Lancet Microbe, doi:10.1016/S2666-5247(23)00393-2.sciencedirect.com, doi.org.

14. Kosakovsky Pond et al., Anti-COVID drug accelerates viral evolution, Nature, doi:10.1038/d41586-023-03248-3.nature.com, doi.org.

15. twitter.com, twitter.com/LongDesertTrain/status/1597353291868155906.twitter.com/LongDesertTrain/status/1597353291868155906.

Pakotiprapha et al., 13 May 2024, peer-reviewed, 6 authors.

In Vitro studies are an important part of preclinical research, however results may be very different in vivo.

This Paper Molnupiravir All

{ 'indexed': {'date-parts': [[2024, 5, 14]], 'date-time': '2024-05-14T00:37:14Z', 'timestamp': 1715647034068}, 'reference-count': 0, 'publisher': 'American Society for Pharmacology and Experimental Therapeutics', 'content-domain': {'domain': [], 'crossmark-restriction': False}, 'published-print': {'date-parts': [[2024, 6]]}, 'DOI': '10.1124/jpet.212.937140', 'type': 'proceedings-article', 'created': {'date-parts': [[2024, 5, 13]], 'date-time': '2024-05-13T22:52:53Z', 'timestamp': 1715640773000}, 'source': 'Crossref', 'is-referenced-by-count': 0, 'title': 'Molnupiravir Active Metabolite–N4 hydroxycytidine causes Cytotoxicity to Mammalian Cells<i>In ' 'Vitro</i>', 'prefix': '10.1124', 'author': [ {'given': 'Jessada', 'family': 'Pakotiprapha', 'sequence': 'first', 'affiliation': []}, {'given': 'Krittin', 'family': 'Tangjittham', 'sequence': 'additional', 'affiliation': []}, {'given': 'Tanaboon', 'family': 'Rimdusit', 'sequence': 'additional', 'affiliation': []}, {'given': 'Onmanee', 'family': 'Prajuabjinda', 'sequence': 'additional', 'affiliation': []}, {'given': 'Saovapak', 'family': 'Poomirat', 'sequence': 'additional', 'affiliation': []}, {'given': 'Sutheera', 'family': 'Sangsiri', 'sequence': 'additional', 'affiliation': []}], 'member': '36', 'published-online': {'date-parts': [[2024, 5, 13]]}, 'event': 'ASPET 2024 Annual Meeting Abstract', 'container-title': 'ASPET 2024 Annual Meeting Abstract - Toxicology', 'original-title': [], 'link': [ { 'URL': 'https://syndication.highwire.org/content/doi/10.1124/jpet.212.937140', 'content-type': 'unspecified', 'content-version': 'vor', 'intended-application': 'similarity-checking'}], 'deposited': { 'date-parts': [[2024, 5, 13]], 'date-time': '2024-05-13T22:52:54Z', 'timestamp': 1715640774000}, 'score': 1, 'resource': {'primary': {'URL': 'http://jpet.aspetjournals.org/lookup/doi/10.1124/jpet.212.937140'}}, 'subtitle': [], 'short-title': [], 'issued': {'date-parts': [[2024, 5, 13]]}, 'references-count': 0, 'alternative-id': ['10.1124/jpet.212.937140'], 'URL': 'http://dx.doi.org/10.1124/jpet.212.937140', 'relation': {}, 'subject': [], 'published': {'date-parts': [[2024, 5, 13]]}}

Download Image

Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.

Submit

Post

@CovidAnalysis

FAQ

Public domain CC0 1.0